2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

2585 Automated, quality-controlled quantification of metabolic tumor volume and total lesion glycolysis from routine FDG-PET/CT in multiple myeloma

Omkar Bhabad, Larry Grullon-Polanco, N/A2, Myles Kim, PhD3, Robert Norberg4, Omar Alexis Castaneda Puglianini, MD5, Hien Liu, MD6, Melissa Alsina, MD7, Taiga Nishihori, MD8, Kenneth H. Shain, MD, PhD9, Ariosto Siqueira Silva, PhD10, Rachid Baz, MD11, Brandon Blue, MD12, Ariel Grajales-Cruz, MD13, Doris K. Hansen, MD14, John L Cleveland, PhD15, Frederick L. Locke, MD16, Justyn Y Nakashima, MD17, Nicholas Figura, MD18, Yoganand Balagurunathan, PhD19, Rolf Petter Tonseth20, Ghulam Rasool, PhD21, Aaron Wong22, Simon Harrison, MBBS, FRCPath, MRCP, PhD, FRACP23, Mark Raymond Dowling, PhD24, Ciara Louise L Freeman, MD, PhD25
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Moffitt Cancer Center, Tampa, Florida, United States
19 Moffitt Cancer Center, Tampa, Florida, United States
20 BC Cancer Agency, Vancouver, British Columbia, Canada
21 Moffitt Cancer Center, Tampa, Florida, United States
22 Peter MacCallum Cancer Centre, Melbourne, Australia
23 Peter MacCallum Cancer Centre, Melbourne, Australia
24 Peter MacCallum Cancer Centre, Melbourne, Australia
25 Moffitt Cancer Center, Tampa, Florida, United States

Introduction

FDG-PET/CT derived metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are prognostic in multiple myeloma (MM) but use in routine care is limited by labor-intensive whole-body lesion delineation and inconsistent capture of diffuse skeletal and extramedullary disease (EMD). We developed a fully automated, quality-controlled pipeline to quantify skeletal MTV/TLG from standard-of-care FDG-PET/CT, with a dedicated EMD module, and evaluated technical reliability, concordance with expert PERCIST reads, biologic validity, and prognostic value in relapsed/refractory MM (RRMM) treated with BCMA CAR-T therapy.

Methods

This IRB-approved single-center retrospective study (Pro00087316) included RRMM patients treated with BCMA CAR-T who underwent baseline skull-to-mid-thigh or whole-body 18F-FDG PET/CT before infusion. Baseline scans were processed on identical images using three approaches: Tool-M, which combines CT bone segmentation with TotalSegmentator, decay-corrected SUV, and a liver-referenced adaptive threshold based on a 45-mm sphere median plus 3 MAD; the off-the-shelf AutoPET restricted to bone; and Ref-P, a prior radiologist-adjudicated PERCIST 41%-SUVmax reference read as previously described (Freeman et al, Blood 2025). Quality control assesses liver-reference validity, organ-mask completeness, and metabolic preparation.

Impact on progression free survival (PFS) was then modeled using Cox regression with log-transformed MTV. Incremental prognostic value was assessed as the gain in optimism-corrected Harrell C-index over a clinical model which included high-risk cytogenetics, pre-CART bone marrow plasma-cell (BMPC) percentage, LDH, and baseline EMD. Paired bootstrap 95% confidence intervals compared methods. Comparisons were made between BMPC percentage and soluble BCMA (sBCMA) provided they were obtained within 14 days of PET scan.

Results

Among 445 patients with evaluable baseline PET, higher automated MTV predicted inferior PFS (HR 1.18 per log-MTV, p<0.001; adjusted HR 1.12, p=0.002), with separation by median split (log-rank p<0.001). Tool-M was the only PET method that significantly improved discrimination beyond the clinical model (C-index from 0.636 to 0.665), outperforming AutoPET (0.64) and radiologist PERCIST (Ref-P, 0.628). The paired gain favored Tool-M over AutoPET (delta C +0.025, 95% CI +0.001 to +0.045). For TLG, Tool-M also added significant prognostic value (delta C +0.028, p=0.003), whereas AutoPET TLG did not (p=0.087).

Among 143 patients with Ref-P reads, Tool-M ranked patients most closely with expert PERCIST (Spearman 0.80 as compared with 0.77 for AutoPET) and measured systematically higher MTV (Bland-Altman bias +0.85 log-units), consistent with capture of diffuse skeletal disease falling below focal PERCIST thresholds. Tool-M MTV correlated with sBCMA (Spearman rho=0.39, p<0.001) more strongly than with single-site marrow plasma-cell percentage (rho=0.18, p<0.001), supporting whole-body biologic validity. Skeletal MTV was markedly higher in patients with active EMD (median 66.8 vs 9.8 mL, p<0.001), and EMD status improved model discrimination (C-index 0.607 to 0.636; HR 1.67), supporting separate EMD adjudication. QC performance was robust, with 0/449 liver-reference failures, approximately 99% organ-mask completeness, and median blood glucose 92 mg/dL. Preliminary external validation performed in an independent cohort from Peter MacCallum Cancer Centre (n=24) showed excellent concordance (Spearman rho=0.955).

Conclusions

A fully automated, quality-controlled FDG-PET/CT pipeline quantified skeletal MTV and TLG at scale from routine imaging in RRMM patients treated with BCMA CAR-T. Automated MTV was independently prognostic, added discrimination beyond established clinical risk factors, tracked sBCMA, and captured diffuse skeletal disease not fully reflected by focal PERCIST reads. In addition, it outperformed an off-the-shelf AutoPET approach and as the workflow is DICOM-based, it may be adaptable across imaging environments with local QC and validation. These findings support automated PET-derived MTV/TLG as a scalable tumor-burden measure for risk stratification in multiple myeloma.

Omkar Bhabad: No relevant conflicts of interest to declare.